But-2-enedioic acid--ethenylbenzene (1/1) | 25300-64-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: But-2-enedioic acid--ethenylbenzene (1/1)
• 英文别名: but-2-enedioic acid;styrene
• CAS: 25300-64-5
• 化学式: C12H12O4
• 分子量: 220.22
• InChiKey: LFWGYTIGZICTTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.464
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS
  申请人：TUFTS MEDICAL CENTER

  公开号：US20160052982A1

  公开（公告）日：2016-02-25

  The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest.

  本申请提供了制备可溶性脂质化配体药剂的方法，包括配体实体和脂质实体，并在某些实施例中提供了这些组分的相关参数，从而使得能够适当选择组分来组装出针对任何感兴趣的靶点的活性药剂。
• Radioactive iodine-labeled compound
  申请人：FUJI PHOTO FILM CO., LTD.

  公开号：US20040228793A1

  公开（公告）日：2004-11-18

  A radioactive iodine-labeled compound represented by the following formula 1 wherein X represents a radioactive iodine atom which may substitute at an arbitrary position on the benzene ring (preferably 123 I, 125 I and the like.), n represents an integer of 1 to 3, R 1 and R 2 each independently represent a substituted or unsubstituted alkyl group, Y represents an alkylene group having 1 to 6 carbon atoms (preferably methylene group), M represents a counter ion, and m represents the number of ions required to neutralize the charge of the molecule. A radioactive iodine-labeled compound that can selectively accumulate in tumor cells or tumor tissue and a scintillation imaging agent containing the compound are provided.

  以下是该公式代表的放射性碘标记化合物： 其中X代表一个放射性碘原子，可以替代苯环上的任意位置（优选为 123 I， 125 I等），n代表1到3的整数，R 1 和R 2 分别独立代表取代或未取代的烷基基团，Y代表具有1到6个碳原子的烷基基团（优选为亚甲基基团），M代表一个对离子，m代表中和分子电荷所需的离子数。提供了一种可以选择性地在肿瘤细胞或肿瘤组织中积累的放射性碘标记化合物以及含有该化合物的闪烁成像剂。
• [EN] CRYSTALLINE FORMS OF A LYSYL OXIDASE-LIKE 2 INHIBITOR AND METHODS OF MAKING<br/>[FR] FORMES CRISTALLINES D'UN INHIBITEUR DE LYSYL OXYDASE DE TYPE 2 ET LEURS PROCÉDÉS DE FABRICATION
  申请人：PHARMAKEA INC

  公开号：WO2018048943A1

  公开（公告）日：2018-03-15

  Described herein are crystalline forms of pharmaceutically acceptable salts of the lysyl oxidase-like 2 (LOXL2) inhibitor (3-(4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yloxy)phenyl)((3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-yl)methanone. Also described are methods of making the LOXL2 inhibitor, pharmaceutical compositions and medicaments comprising the LOXL2 inhibitor, and methods of using the LOXL2 inhibitor in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

  本文描述了赖氨酸氧化酶样2（LOXL2）抑制剂（3-（4-（氨甲基）-6-三氟甲基吡啶-2-氧基）苯基）（（3R,4R）-3-氟-4-羟基吡咯烷-1-基）的药用盐的晶体形式。还描述了制备LOXL2抑制剂的方法，包含LOXL2抑制剂的药物组合物和药物，以及在治疗与LOXL2活性相关的状况、疾病或障碍中使用LOXL2抑制剂的方法。
• [EN] POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF<br/>[FR] ANTAGONISTE LPA1 POLYCYCLIQUE ET UTILISATIONS DE CELUI-CI
  申请人：AMIRA PHARMACEUTICALS INC

  公开号：WO2012078805A1

  公开（公告）日：2012-06-14

  Described herein is the LPA1 antagonist 1- 4'-[3-methyl-4-((R)- l-phenyl-ethoxycarbonylamino)- isoxazol-5-yl]-biphenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPA1 antagonist, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions suitable for administration to a mammal that include the LPA1 antagonist, or pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating LPA-dependent or LPA- mediated diseases or conditions.

  本文描述了LPA1拮抗剂1-4'-[3-甲基-4-((R)- l-苯基-乙氧羰基氨基)-异噁唑-5-基]-联苯基-4-基}-环丙烷羧酸（化合物1），或其药用盐。还描述了制备LPA1拮抗剂或其药用盐的方法，以及适用于哺乳动物的药物组合物，包括LPA1拮抗剂或其药用盐，并且使用这种药物组合物治疗依赖于LPA或LPA介导的疾病或病症的方法。
• DP2 Antagonist and Uses Thereof
  申请人：BRITTAIN Jason Edward

  公开号：US20110034558A1

  公开（公告）日：2011-02-10

  Described herein is the DP 2 antagonist [2′-(3-benzyl-1-ethyl-ureidomethyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl]-acetic acid, or a pharmaceutically acceptable salt thereof. Also described are methods of preparing the DP2 antagonist, or a pharmaceutically acceptable salt thereof. Also described herein are pharmaceutical compositions suitable for administration to a mammal that include the DP 2 antagonist, or a pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating respiratory diseases or conditions, allergic diseases or conditions, inflammatory diseases or conditions, as well as other prostaglandin D 2 -dependent or prostaglandin D 2 -mediated diseases or conditions.

  本文描述了DP2拮抗剂[2'-(3-苄基-1-乙基-脲甲基)-6-甲氧基-4'-三氟甲基-联苯-3-基]-乙酸，或其药用盐。还描述了制备DP2拮抗剂或其药用盐的方法。本文还描述了适合用于哺乳动物的药物组合物，包括DP2拮抗剂或其药用盐，并描述了使用这种药物组合物治疗呼吸道疾病或症状、过敏性疾病或症状、炎症性疾病或症状，以及其他前列腺素D2依赖性或前列腺素D2介导的疾病或症状的方法。